Web Exclusives

Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing

A new study presented at ASCO 2018 showed that the use of next-generation sequencing of metastatic non–small-cell lung cancer tumors to test for all known cancer-related genetic mutations was more cost-effective and provided faster results than testing for a single genetic mutation.

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

A new retrospective analysis presented at ASCO 2018 lends support to precision medicine in cancer. In the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) clinical trial, selecting a targeted therapy based on patients’ tumor molecular analyses independently predicted longer overall survival (OS) compared with nonmatched therapy across a [ Read More ]

The Patient Voice Is Key to Value-Based Care

“It’s the disease of not listening that I am troubled with,” a quote attributed to King Henry IV, kicked off a spirited panel discussion on the importance of incorporating the patient’s voice during treatment. Experts addressed these challenges at the 2018 Association of Community Cancer Centers Annual Meeting & Cancer [ Read More ]

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

“Communication is a beautiful thing, and we stress that a lot in our clinic. The longer a patient is on pain medicine, the harder it is to come off of it and the more it’s going to predict issues later on, so we have to continue to be vigilant,” Ms. Edwards

Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer

San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).

Combining Immunotherapy and Radiotherapy Shows Good Synergy

As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

The National Comprehensive Cancer Network (NCCN)’s first guideline (version 1.2018) for the management of side effects from immunotherapy recognizes “a new spectrum of adverse events” in patients who are receiving immune checkpoint inhibitor therapy, said John A. Thompson, MD, Director, Phase I Clinical Trials Program, Fred Hutchinson Cancer Research Center, [ Read More ]

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

New results from the international, randomized, phase 3 clinical trial QuANTUM-R show that the targeted drug quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation, the most common FLT3 gene mutation, affecting [ Read More ]

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer. All node-negative (N0) patients had triple-negative breast cancer (TNBC), as did the majority of patients with low-volume nodal disease (N1); the remainder of the [ Read More ]

Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma

Atlanta, GA—Mogamulizumab, a monoclonal antibody targeting CC chemokine receptor type 4 (CCR4), significantly reduced the risk for disease progression or death in patients with untreated cutaneous T-cell lymphoma (CTCL) compared with vorinostat (Zolinza), reported Youn H. Kim, MD, Director, Multidisciplinary Cutaneous Lymphoma Program, Stanford Medicine, California, at ASH 2017. Patients [ Read More ]

Sign me up!